NCT06455514PHASE1Recruiting

Post-CA Neuroprotection With Magnesium

NYU Langone Health

Start Date

3/25/2025

Completion Date

6/30/2026

Summary

The purpose of this pilot interventional study is to collect preliminary data on administering magnesium sulfate as a neuroprotective medication in patients who achieved Return of Spontaneous Circulation (ROSC) following Cardiac Arrest (CA). The primary aims are to assess the feasibility and safety of administering magnesium and measure serum markers of neuronal injury at prespecified time points in the post-cardiac arrest period. Because this is a pilot study with a limited sample size, the primary objective is to evaluate the precision and stability of the collected measures to inform the design and formal analysis in a larger trial.

Eligibility Criteria

Age Range: 18 years to 85 years

Inclusion Criteria: * Documented post-cardiac arrest patient with Return of Spontaneous Circulation (ROSC) achieved \<2 hours prior to recruitment Exclusion Criteria: * Age \< 18 years or \> 85 years * Traumatic cardiac arrests * Unsustained ROSC (\<20 minutes) * Patient who is responsive/able to follow motor commands within 1 hour of achieving ROSC * Plan for withdrawal of life support within 72 hours of ROSC * Known pregnant women at the time of the cardiac arrest * Known prisoners at the time of the cardiac arrest * Subjects who have a medical o social condition that would make them inappropriate for the study based on the PI's or clinical team judgement.

Interventions

DRUG

Magnesium Sulfate

DRUG

Saline

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Cardiac ArrestReturn of Spontaneous Circulation

Locations

NYU Langone Health

New York, New York 10016

United States